D(3) dopamine receptor Antibodies

D(3) dopamine receptor (DRD3)

Dopamine receptor whose activity is mediated by G proteins that inhibit adenylyl cyclase. Promotes cell proliferation.

.

Gene Information

Human
Gene Name:	DRD3
Uniprot:	P35462
Entrez:	1814

Family

Belongs to:
G-protein coupled receptor 1 family

Alternative Names

D(3) dopamine receptor; D3DR; Dopamine D3 R; Dopamine D3 receptor; Dopamine D3R; dopamine receptor D3; DRD3; essential tremor 1; ETM1; FET1; MGC149204; MGC149205

Molecular Weight

Mass (kDA):
44.225 kDA

Genomic Context

Human
Location:	3q13.31
Sequence:	3; NC_000003.12 (114127580..114199407, complement)

Tissue Specificity

Brain.

Subcellular Localizations

Cell membrane; Multi-pass membrane protein. Both membrane-bound and scattered in the cytoplasm during basal conditions. Receptor stimulation results in the rapid internalization and sequestration of the receptors at the perinuclear area (5 and 15 minutes), followed by the dispersal of the receptors to the membrane (30 minutes). DRD3 and GRK4 co-localize in lipid rafts of renal proximal tubule cells.

Diseases

• Schizophrenia
• Parkinson Disease
• Dyskinetic Syndrome
• Psychotic Disorders
• Depressive Disorder
• Mental Disorders
• Bipolar Disorder
• Lingual-facial-buccal Dyskinesia
• Dysequilibrium Syndrome
• Dyskinesia, Drug-induced
• Variable Number Tandem Repeat

• Catalepsy
• Stereotyped Behavior
• Mood Disorders
• Nervousness
• Attention Deficit Hyperactivity Disorder
• Substance-related Disorders

Pathways

• Locomotion
• Pathogenesis
• Localization
• Sensitization
• Secretion
• Cognition
• Dopamine Uptake
• Transport
• Innervation
• Prolactin Secretion
• Brain Development
• Reverse Transcription
• Excretion

• Aging
• Methylation
• Dna Methylation
• Habituation
• Natriuresis
• Cell Proliferation
• Hypersensitivity

PTMs

• Phosphorylation
• Methylation

• Glycosylation
• Reduction

• Cleavage

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/DRD3

Best Uses of the DRD3 Marker in Boster Bio

There are many aspects to consider when choosing an anti-dopaminergic D3 marker. This article will provide an overview of the Anti-DRD3 Marker. It includes its applications, validation, pricing, and pricing. Additionally, you will learn how to use it for different types of experiments. This article will give you some useful tips if you are new to the field.

Anti-Dopamine Receptor D3/DRD3 Marker

Boster Bio's Anti-Dopamine Receptor D3 Marker (DRD3) reacts with human, mouse, and rat samples. This antibody is suitable for studies in the areas of neuroinflammation, immunohistochemistry, and Western blot. It can detect dopamine receptors D3 in a variety tissues.

The antibody was validated using a variety of platforms, including positive and negative samples. It was found to be highly specific and affinity. It also rewards first-time reviewers with product credits. Scientists in research and design now use the company's products. They're currently the leading source of anti-DRD3 antibodies. They are the preferred choice of researchers all over the world.

The DRD3 proteins are important for the sorting mammamoles in the endocytic systems. This protein interacts with the G protein-coupled receptor, COPI. Prazosin blocks the GPCR-mediated sorting DRD3 by stabilizing the transient interactions between DRD3 & the coatomer COPI. RNAi knockdowns in DRD3 inhibit endocytic sorts, which suggests a noncanonical role that this G-proteincoupled receptor plays in this process.

DRD3 was previously identified in human, mouse, and rat astrocytes. It is interesting to note that the levels of this protein are significantly higher in Alzheimer’s disease patients. DRD3 expression may be an indication of a pathological mechanism because the disease involves chronic neuroinflammation. It is also associated w/inhibition of cAMP synthesis, which favors the conversion of glial cells between pro-inflammatory and non-inflammatory.

The DRD3 molecular is involved in neuroinflammation and has been linked to Parkinson's disease. In Parkinson's disease mouse models, the absence of DRD3 reduces microglial activity. DRD3 also reduces neuroinflammation. In addition, DRD3 binds to IL-4 in glial cultures.

DRD3 is present in many brain structures. DRD3 is present in many brain structures, including astrocytes. However, it is not found in microglia. DRD3 deficiency caused a decrease of microglial activation in mice, while DRD3KO mice had a higher M1-toM2 ratio. Additionally, DRD3 knockout mice had an exacerbated M1-to-M2 ratio in astrocytes and an increased expression of the anti-inflammatory protein Fizz1 in microglia.

Applications

The DRD3 marker is found in the limbic brain, nucleus, accumbens, septi, and Calleja island. These markers are related to G-protein coupling proteins that are responsible for regulating dopamine levels. These receptors are abundantly expressed in the brain and have many applications. The purpose of this study was to determine if DRD3 is expressed in these areas.

We used a vector that codifies the green fluorescent Protein (GFP), reporter gene, as well as a scrambled ShRNA to measure Drd3 levels in hepatocytes. This combination was transfected into human hepatocytes using a lentiviral vector codifying the green fluorescent protein (GFP) reporter gene and a scrambled shRNA. Quantifications were done in 48 hours. To confirm our findings, the DRD3 knockdown model was used to study the functional role that the DRD3 marker plays in endocytic transportation.

Validation

The DRD3 gene encodes a protein called DRD3, and has been detected in microglial cell and astrocytes. DRD3 is essential for activation of microglia. A deficiency in this gene results in unresponsive microglia and an increased M1-toM2-ratio in microglia. Furthermore, DRD3 is known to contribute to the secretion of the anti-inflammatory enzyme Fizz1.

DRD3 is an essential component of glia that are involved in neuroinflammation. Numerous studies have shown mice lacking DRD3 were more susceptible to neuroinflammation. PG01037 is a chemical that can cross the blood-brain border and reduces neurodegeneration. Hence, a functional DRD3 antibody can be useful in the detection of glia.

To validate the Boster bio DRD3 marker, silencing experiments were performed. Our model system was primary murine fibroblasts. We used siRNA pools from Sigma, Dopamine Smad, and ONTARGETplus Nontargeting Control. We transfected control cellular cells with 50nM of siRNA combined with Lipofectamine, RNAiMAX.

The DRD3 marker has been validated. Fizz1 protein expression was three times higher in mice treated with systemic LPS than in controls. We also found that IL-1b was not detectable under any conditions. Our results demonstrate that DRD3 has a crucial role in activating microglia. In a second study, we will examine DRD3's function in glial cell activation.